EBR Systems, Inc. EBRCZ

FY2025 · ended Dec 31, 2025 · Revenue $1.62M · Filed Mar 18, 2026

EBR Systems, Inc. (EBRCZ) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.6 million and a net loss of $48.8 million. Free cash flow was -$56.9 million. As of Jun 30, 2026 it held $86.9 million in cash and investments and $60.3 million in total debt.

Revenue (TTM)
$6.45M
Net income (TTM)
$-60.76M
Operating cash flow (TTM)
$-65.60M
Free cash flow (TTM)
$-74.47M
EPS (TTM)
$-0.14
Dividend per share
None
Shares outstanding
450.44M
+20.8% vs prior year
Net cash
$26.66M
as of Jun 30, 2026
Operating margin
-895.8%
FY 2026

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
EBRCZ (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Sunnyvale, CA
SEC filer status
, Emerging growth company
SEC CIK
1347123
Former names
EBR Systems Inc (until Feb 10, 2011)

Other Surgical & Medical Instruments & Apparatus companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
$1.6M
—
Operating income
-$46.1M
-$38.3M
Net income
-$48.8M
-$40.8M
Diluted EPS
-$0.12
-$0.13
Operating cash flow
-$53.2M
-$41.2M
Free cash flow
-$56.9M
-$41.5M
Total assets
$97.2M
$73.6M
Total liabilities
$71.6M
$49.2M
Stockholders' equity
$25.6M
$24.4M
Cash and investments
$54.2M
$66.0M
Total debt
$59.5M
$42.9M

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Officer or director change, Other events
Aug 24, 2026 Aug 20, 2026
8-K Current report
Shareholder vote results
Aug 20, 2026 Aug 18, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Material agreement, Unregistered share sale
Jun 10, 2026 Jun 4, 2026
10-Q Quarterly report May 11, 2026 Mar 31, 2026
8-K Current report
Shareholder vote results
May 7, 2026 May 6, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.